(Arg)9 (Synonyms: Nona-L-arginine; Peptide R9)

Cat. No.: HY-P0133: FAQs
Data Sheet Handling Instructions

Molarity Calculator

(Arg)9 (Nona-L-arginine) is a cell-penetrating peptide (CPP) made up of 9 arginine residues. (Arg)9 has neuroprotective property, exhibits neuroprotective activity with an IC₅₀ of 0.78 μM in the glutamic acid model.

At equivalent molar concentrations, both the salt and free forms of a compound exhibit comparable biological activity. Nevertheless, the salt form ((Arg)9 acetate) usually boasts enhanced water solubility and stability.

For research use only. We do not sell to patients.

(Arg)9 Chemical Structure

CAS No. : 143413-47-2

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of (Arg)9:

(Arg)9 TFA Get quote
(Arg)9 acetate Get quote

1 Publications Citing Use of MCE (Arg)9

•In Vitro Cell Dev Biol-Pl. 06 January 2022.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

IC50: 0.78 μM (neuroprotection)^[1]

In Vitro

(Arg)9 (Nona-L-arginine; 5-10 μM) provides significant neuroprotection in a dose–response manner following glutamic acid exposure (IC₅₀=0.78 μM). Following kainic acid exposure, (Arg)9 is neuroprotective, but less effective than in the glutamic acid model (IC₅₀=0.81 μM). (Arg)9 also shows neuroprotection following in vitro ischemia (IC₅₀=6 μM)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

(Arg)9 (Nona-L-arginine; 1?μM/kg (600? μL); i.v.; once, for 30min; male Sprague–Dawley ratspermanent middle cerebral artery stroke model) shows neuroprotective effects and reduces infarct volume^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague–Dawley rats (270 to 320 g) permanent middle cerebral artery stroke model^[2]
Dosage:	1 μM/kg (600 μL)
Administration:	Intravenous injection; once, over 5 minutes
Result:	Reduced significantiy 20% in infarct volume.

Molecular Weight

1423.69

Formula

C₅₄H₁₁₀N₃₆O₁₀

CAS No.

143413-47-2

Sequence

Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg

Sequence Shortening

RRRRRRRRR

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Solvent & Solubility

In Vitro:

H₂O

Peptide Solubility and Storage Guidelines:

1. Calculate the length of the peptide.

2. Calculate the overall charge of the entire peptide according to the following table:

	Contents	Assign value
Acidic amino acid	Asp (D), Glu (E), and the C-terminal -COOH.	-1
Basic amino acid	Arg (R), Lys (K), His (H), and the N-terminal -NH₂	+1
Neutral amino acid	Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q)	0

3. Recommended solution:

Overall charge of peptide	Details
Negative (<0)	1. Try to dissolve the peptide in water first. 2. If water fails, add NH₄OH (<50 μL). 3. If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (>0)	1. Try to dissolve the peptide in water first. 2. If water fails, try dissolving the peptide in a 10%-30% acetic acid solution. 3. If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0)	1. Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first. 2. For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Meloni BP, et, al. The neuroprotective efficacy of cell-penetrating peptides TAT, penetratin, Arg-9, and Pep-1 in glutamic acid, kainic acid, and in vitro ischemia injury models using primary cortical neuronal cultures. Cell Mol Neurobiol. 2014 Mar;34(2):173-81. [Content Brief]

[2]. Meloni BP, et, al. Poly-arginine and arginine-rich peptides are neuroprotective in stroke models. J Cereb Blood Flow Metab. 2015 Jun;35(6):993-1004. [Content Brief]

(Arg)9 Related Classifications

Neurological Disease

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

(Arg)9143413-47-2Nona-L-arginine Peptide R9Peptide R9Peptide R 9Peptide R-9Otherscell-penetrating peptideneuroprotective propertyarginineinfarct volumeInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks